John S March1, Benedetto Vitiello. 1. Division of Neurosciences Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. john.march@duke.edu
Abstract
OBJECTIVE: The purpose of this report was to summarize the key clinical messages from the Treatment for Adolescents with Depression Study (TADS). METHODS:TADS is a National Institute of Mental Health (NIMH)-funded randomized controlled trial designed to evaluate the relative effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and the combination of fluoxetine plus CBT across acute treatment, maintenance treatment, and naturalistic follow-up periods among adolescents with major depressive disorder. RESULTS: Findings revealed that 6 to 9 months of combined fluoxetine plus CBT should be the modal treatment from a public health perspective as well as to maximize benefits and minimize harms for individual patients. CONCLUSION: The combination of fluoxetine and CBT appears to be superior to both CBT monotherapy and fluoxetine monotherapy as a treatment for moderate to severe major depressive disorder in adolescents.
RCT Entities:
OBJECTIVE: The purpose of this report was to summarize the key clinical messages from the Treatment for Adolescents with Depression Study (TADS). METHODS: TADS is a National Institute of Mental Health (NIMH)-funded randomized controlled trial designed to evaluate the relative effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and the combination of fluoxetine plus CBT across acute treatment, maintenance treatment, and naturalistic follow-up periods among adolescents with major depressive disorder. RESULTS: Findings revealed that 6 to 9 months of combined fluoxetine plus CBT should be the modal treatment from a public health perspective as well as to maximize benefits and minimize harms for individual patients. CONCLUSION: The combination of fluoxetine and CBT appears to be superior to both CBT monotherapy and fluoxetine monotherapy as a treatment for moderate to severe major depressive disorder in adolescents.
Authors: John March; Helena C Kraemer; Madhukar Trivedi; John Csernansky; John Davis; Terence A Ketter; Ira D Glick Journal: Neuropsychopharmacology Date: 2010-08-25 Impact factor: 7.853
Authors: X Zhang; P J Nicholls; G Laje; T D Sotnikova; R R Gainetdinov; P R Albert; G Rajkowska; C A Stockmeier; M C Speer; D C Steffens; M C Austin; F J McMahon; K R R Krishnan; M A Garcia-Blanco; M G Caron Journal: Mol Psychiatry Date: 2010-09-21 Impact factor: 15.992
Authors: Eva Henje Blom; Larissa G Duncan; Tiffany C Ho; Colm G Connolly; Kaja Z LeWinn; Margaret Chesney; Frederick M Hecht; Tony T Yang Journal: Front Hum Neurosci Date: 2014-08-19 Impact factor: 3.169